REV3L

Across TCGA pan-cancer cohorts, REV3L mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of REV3L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where REV3L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types REV3L is over-expressed in tumor, although a few such as PDAC and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and PDAC are the cancer types where REV3L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in REV3L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.283	<.001	8	view →
LUAD	Female	II,III,IV	+0.932	<.001	2	view →
PDAC	All	All	−1.253	.048	1	view →
LSCC	Female	III,IV	−0.820	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

REV3L–CCRCC

Open the CCRCC breakdown →